TICKERNERD
Menu
CTSOCTSOHealthcare · Medical Devices

CTSO Stock Forecast: CytoSorbents Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$6.41

The 1 Wall Street analysts covering CytoSorbents Corp. hold a median 12-month price target of $48 — +641.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$20.2M
Ticker Nerd rank
47 / 100
Median analyst target
$48
Analysts covering
1
Revenue$9.6M+0.2% y/y
Operating income−$2.4M
Net income−$4.4M
Free cash flow−$635K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

CTSO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CytoSorbents Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
47 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Size
88
Growth
65
Quality
56
Value
49
Volatility
46
Revisions
29
Issuance
24
Momentum
20

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (20): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTSO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTSO, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Low $15Median $48High $80

The green dot is the last close — the median target sits +641.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Mar 2026D. Boral CapitalMaintainsBuy$10
12 Jan 2026D. Boral CapitalMaintainsBuy—
16 Dec 2025D. Boral CapitalMaintainsBuy—
14 Nov 2025D. Boral CapitalMaintainsBuy—
14 Nov 2025HC Wainwright & Co.MaintainsNeutral—
16 Sept 2025D. Boral CapitalMaintainsBuy—
20 Aug 2025D. Boral CapitalMaintainsBuy—
8 Aug 2025D. Boral CapitalMaintainsBuy—
21 July 2025D. Boral CapitalMaintainsBuy—
25 June 2025D. Boral CapitalMaintainsBuy—
15 May 2025D. Boral CapitalMaintainsBuy—
15 May 2025HC Wainwright & Co.ReiteratesNeutral—
2 May 2025D. Boral CapitalMaintainsBuy—
3 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
1 Apr 2025D. Boral CapitalMaintainsBuy—
25 Feb 2025D. Boral CapitalMaintainsBuy—
13 Jan 2025D. Boral CapitalMaintainsBuy—
3 Jan 2025D. Boral CapitalMaintainsBuy—
12 Nov 2024D. Boral CapitalMaintainsBuy—
11 Nov 2024HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTSO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CTSO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

CytoSorbents Corp. (CTSO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.5×

Cheaper than 86% of US stocks

Price / sales
0.5×

Cheaper than 81% of US stocks

Price / book
−27.2×

Cheaper than 99% of US stocks

EV / EBITDA
−4.4×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
0.2%

Higher than 28% of US stocks

Earnings growth (YoY)
0.2%

Higher than 36% of US stocks

Gross margin
73.2%

Higher than 85% of US stocks

Operating margin
−24.6%

Higher than 21% of US stocks

Net margin
−48.9%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−336.2%

Higher than 5% of US stocks

Return on assets
−17.1%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CytoSorbents Corp. (CTSO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CytoSorbents Corp. has a market value of $20.2M and an enterprise value of $45.2M.

  • Revenue in the twelve months to 30 June 2026: $37.2M. The latest quarter grew 0.2% year on year.

  • Net income over the same four quarters: −$18.2M, a −48.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−5.80.

  • Free cash flow in the twelve months to 30 June 2026: −$9.6M.

  • Shares outstanding: 3.1M.

  • Trailing P/E: −2.5×; forward P/E: −5.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • CytoSorbents Corp. employs 129 people — $288K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CTSO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CTSOCytoSorbents Corp.$20.2M
47
LFWDLifeward Ltd.$20.0M
22
MODDModular Medical, Inc.$20.7M
11
PLSMPulsenmore Ltd.$16.4M
34
NMTCNeuroOne Medical Technologies Corp.$14.2M
39
ARAYAccuray, Inc.$29.7M
31
HSCSHeartSciences, Inc.$13.2M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CytoSorbents Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTSO news & analysis

CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 10 Sept 2026neutral

CytoSorbents Corporation announced it will participate in the upcoming H.C. Wainwright 28th Annual Global Investment Conference, as disclosed in a Sept. 10, 2026 press release from Princeton, N.J. The company, which specializes in blood purification for life-threatening conditions in the intensive care unit and cardiac surgery, noted its attendance at the event.

Why it matters — A CTSO watcher would care because the company's participation at a major investment conference provides an opportunity for leadership to present to investors and potentially raise its visibility in the financial community.

CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Newsfile Corp · 4 Sept 2026neutral

CytoSorbents announced that CEO Dr. Phillip Chan and CFO Peter Mariani will attend the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on September 9-10, 2026, in New York City, where they will deliver an investor presentation and hold scheduled one-on-one meetings with investors.

Why it matters — CTSO watchers may be interested because the company executives are engaging directly with investors at a life sciences conference, providing an opportunity to share updates on the company.

CytoSorbents Announces Reverse Stock Split

PRNewsWire · 3 Sept 2026neutral

CytoSorbents Corporation announced a previously shareholder-approved one-for-20 reverse stock split of its common stock, intended to support compliance with Nasdaq's $1.00 minimum bid price requirement. The split is expected to become effective and trade on a split-adjusted basis at the market open on September 8, 2026.

Why it matters — The reverse split is a significant corporate action aimed at maintaining compliance with Nasdaq listing requirements, which directly affects CTSO shareholders' holdings and the stock's trading structure.

CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

PRNewsWire · 2 Sept 2026positive

CytoSorbents announced new real-world, patient-level matched data showing intraoperative use of CytoSorb was associated with a significant 37% relative reduction in severe bleeding in urgent CABG patients on ticagrelor, along with reductions in chest tube drainage and red blood cell transfusions and no serious device-related adverse events. The company also reported constructive feedback from recent FDA Pre-Submission meetings on potential U.S. regulatory pathways for DrugSorb-ATR for ticagrelor and direct oral anticoagulant removal in urgent cardiac surgery.

Why it matters — This data reinforces the STAR-T trial results and is expected to support a planned U.S. FDA De Novo submission for DrugSorb-ATR, advancing a potential regulatory path for the device.

Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Cytosorbents Corporation held its Q2 2026 earnings call, and the full transcript of the call was published by Seeking Alpha.

Why it matters — The transcript provides CTSO watchers with the company's own commentary on its second-quarter 2026 performance and outlook directly from management.

FAQ

Frequently asked questions about CTSO stock

What is the CTSO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering CytoSorbents Corp. have a median 12-month price target of $48, with estimates ranging from $15 to $80. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTSO stock a buy right now?

Of the 1 analysts covering CytoSorbents Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytoSorbents Corp. 47 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTSO?

As at 12 Sept 2026, CytoSorbents Corp. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will CTSO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +641.0% from the last close, and Ticker Nerd's factor model ranks CytoSorbents Corp. 47 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTSO stock forecast for 2030?

No analyst covering CytoSorbents Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTSO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $80 over the next 12 months.

What does CytoSorbents Corp. do?

CytoSorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. CytoSorbents Corporation develops and commercializes products that use hemoadsorption to remove harmful substances from blood, including inflammatory mediators, bilirubin, myoglobin, and certain antithrombotic drugs.

What is the latest news on CTSO?

The most recent item we track (PRNewsWire, 10 Sept 2026): "CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference". CytoSorbents Corporation announced it will participate in the upcoming H.C. Wainwright 28th Annual Global Investment Conference, as disclosed in a Sept. 10, 2026 press release from Princeton, N.J. The company, which specializes in blood purification for life-threatening conditions in the intensive care unit and cardiac surgery, noted its attendance at the event.

Company

About CytoSorbents Corp.

CytoSorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. CytoSorbents Corporation develops and commercializes products that use hemoadsorption to remove harmful substances from blood, including inflammatory mediators, bilirubin, myoglobin, and certain antithrombotic drugs. Its portfolio includes CytoSorb for intensive care and surgical applications, DrugSorb-ATR for removing blood thinners, and additional blood purification and filtration technologies for specialized clinical and veterinary uses. The company serves hospitals and clinicians in the United States, Europe, and other international markets, with an emphasis on treating life-threatening conditions such as sepsis, severe inflammation, and complications associated with surgery and organ failure. Headquartered in Princeton, New Jersey, CytoSorbents Corporation plays a niche role in the medical technology market through its proprietary polymer-based adsorption platform.

CEO Dr. Phillip P. Chan M.D., Ph.D. · 129 employees · United States · https://www.cytosorbents.com